BUZZ - Harmony Biosciences CEO DeNardo to retire, COO to succeed; shares fall

October 12 - ** Harmony Biosciences (HRMY.O) shares fell nearly 4% to $38.79

** The company stated that Chief Operating Officer Peter Anastasiou will become President and CEO on January 1, 2027

** Anastasiou will succeed Jeffrey Dayno, who has served as CEO since 2023 and will retire and step down from the board on December 31

** Anastasiou previously served as CEO of Capsida Biotherapeutics for nearly four years

** The company reaffirmed its FY2026 WAKIX net revenue forecast at $1 billion to $1.04 billion; noted the BP-205 MAD study data is still scheduled for release in the fourth quarter

** Of 11 brokerages, 7 rate the stock “buy” or higher, 3 are “hold,” and 1 “sell”; median target price is $50 — data compiled by LSEG

** As of the last session close, shares were up 7.64% year-to-date

(To assist non-English speakers, Reuters provides its report with automated translation into several other languages. Automated translation may be inaccurate or missing contextual nuance; Reuters does not guarantee the accuracy of automated translations and provides them solely for the convenience of readers. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)